Inhibikase Therapeutics
IKT
13 hedge funds and large institutions have $598K invested in Inhibikase Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 2 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
5.94% less ownership
Funds ownership: 13.97% → 8.03% (-5.9%)
7% less funds holding
Funds holding: 14 → 13 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
78% less capital invested
Capital invested by funds: $2.69M → $598K (-$2.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$31K |
| 2 |
Renaissance Technologies
New York
|
+$7.62K |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$3.33K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$484 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$334 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$696K |
| 2 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$49.8K |
| 3 |
Barclays
London,
United Kingdom
|
-$41.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.93K |
| 5 |
Edgewood Management
Greenwich,
Connecticut
|
-$2 |
IKT Hedge Fund Activity: Q3 2023 in Review
13 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q3 2023, worth a combined $598K — down 78% from $2.69M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IKT and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 8 added.
The largest buyer was Geode Capital Management, adding an estimated $31K. The largest seller was Armistice Capital, cutting an estimated $696K.
- 13 institutional investors held Inhibikase Therapeutics (IKT) as of Q3 2023, down from 14 in Q2 2023.
- Funds reported $598K of Inhibikase Therapeutics stock for Q3 2023, down 78% quarter-over-quarter.
- 1 fund opened new Inhibikase Therapeutics positions in Q3 2023 and 2 closed out, a net change of -1 holder.
- The largest Inhibikase Therapeutics buyer in Q3 2023 was Geode Capital Management, an estimated $31K added.
- The largest Inhibikase Therapeutics seller in Q3 2023 was Armistice Capital, an estimated $696K sold.
Based on aggregated 13F filings for Q3 2023.